SCHEMBL4908172

SCHEMBL4908172

COC(=O)c1ccccc1NC(=O)COc1ccc(OC)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.84
TSHR P16473 3/20 0.84
MAPK10 P53779 3/20 0.84
HSD17B10 Q99714 2/20 0.84
HCAR2 Q8TDS4 1/20 0.80
MAPT P10636 4/20 0.71
RAB9A P51151 4/20 0.71
KMT2A Q03164 2/20 0.71
USP2 O75604 1/20 0.71
MEN1 O00255 1/20 0.71
GAA P10253 1/20 0.71
PKM P14618 1/20 0.71
POLB P06746 1/20 0.69
LMNA P02545 1/20 0.67
KDM4E B2RXH2 2/20 0.67
TDP1 Q9NUW8 1/20 0.67
NPC1 O15118 2/20 0.64
TP53 P04637 1/20 0.63
RECQL P46063 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5696463 0.89 ALDH1A1 (0.85) ALDH1A1TSHRMAPK10HSD17B10HCAR2
SCHEMBL4293558 0.89 ALDH1A1 (0.80) ALDH1A1TSHRMAPK10HSD17B10HCAR2
SCHEMBL5696432 0.89 ALDH1A1 (0.80) ALDH1A1TSHRMAPK10HSD17B10HCAR2
SCHEMBL31239117 0.89 RAB9A (0.80) ALDH1A1TSHRMAPK10HSD17B10HCAR2
SCHEMBL8689332 0.89 HCAR2 (1.00) ALDH1A1TSHRMAPK10HSD17B10HCAR2
SCHEMBL5696442 0.82 ALDH1A1 (0.69) ALDH1A1TSHRMAPK10HSD17B10HCAR2
SCHEMBL5928699 0.82 KMT2A (0.78) ALDH1A1TSHRMAPK10HSD17B10KMT2A
SCHEMBL4297503 0.80 HIF1A (0.80) ALDH1A1TSHRMAPK10HSD17B10HCAR2
SCHEMBL10502377 0.80 KMT2A (1.00) ALDH1A1TSHRMAPK10HSD17B10MAPT
SCHEMBL7435743 0.80 TSHR (1.00) ALDH1A1TSHRMAPK10HSD17B10HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US claimed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US claimed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US claimed
WO-2004091724-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2004-10-28 WO claimed
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US disclosed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US disclosed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US disclosed
WO-2004091724-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus HCCS, ALAD, HAVCR2 ALDH1A1 271/4885TSHR 4195/4885MAPK10 2338/4885
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS HCCS, ALAD, HAVCR2 ALDH1A1 271/4885TSHR 4195/4885MAPK10 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.